Nucleofector 4D: Enhancing Genetic Studies and Transfection Efficiency

What Makes the 4D Nucleofector Unique?

The Lonza 4D platform combines electroporation with proprietary buffers to deliver plasmids directly into the nucleus. Internal QA data (Lonza, 2024) report 90–95 % transfection efficiency in primary T cells—a 30 % gain over conventional cuvette electroporators.

Key Performance Metrics

• Pulse duration: 20–50 ms square waves; adjustable in 1 ms increments.
• Cell viability: >80 % post‑transfection across 12 human cell types (n = 600 runs).
• Throughput: 96‑well shuttle module processes 2,000 samples/day in screening labs.

Best‑Practice Tips

1. Use freshly prepared, endotoxin‑free DNA at < 1.5 kb/μL to minimize arcing.
2. Pre‑equilibrate cells in hypo‑osmolar buffer for 10 min to raise nuclear uptake by 12 %.
3. Monitor impedance; values >0.5 Ohm indicate poor cuvette contact.

Cost‑Benefit Snapshot

Switching from lipid reagents to 4D nucleofection saved a pharma R&D group $38,000 annually in consumables (internal case study, 2025).

Reference
Lonza. “4D Nucleofector Technology Overview,” White Paper, 2024.